BAFNA PHARMACEUTICALS
|
The Current P/E Ratio of BAFNA PHARMACEUTICALS is 42.43.
| Share Price | ₹157.1 | Dec 22,2025 |
| Market Cap | ₹372.3 Cr | |
| Earnings-TTM | ₹8.8 Cr | TTM-Standalone Results |
| Price/Earnings | 42.43x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of BAFNA PHARMACEUTICALS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹372.3 Cr] as on Dec 22,2025
(/) Earnings [ ₹8.8 Cr] based on TTM-Standalone Results
(=) P/E Ratio [ 42.43x ]
Thus, for BAFNA PHARMACEUTICALS , the investors are currently willing to pay 42.43 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of BAFNA PHARMACEUTICALS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of BAFNA PHARMACEUTICALS over the last five years.
Historical PE (Price/Earnings) ratio chart of BAFNA PHARMACEUTICALS
PE Ratio Performance Analysis for BAFNA PHARMACEUTICALS
- BAFNA PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 39.60x.
- BAFNA PHARMACEUTICALS 's operated at median p/e ratio of 42.73x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, BAFNA PHARMACEUTICALS 's p/e ratio peaked in Mar2022 at 57.59x.
- BAFNA PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2023 of 17.24x.
How does BAFNA PHARMACEUTICALS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| BAFNA PHARMACEUTICALS | 8.78 | 42.43 | 372.3 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 10,517.90 | 40.41 | 424,982.0 |
| DIVIS LABORATORIES LTD | 2,485.00 | 69.57 | 172,878.0 |
| CIPLA LTD | 5,453.86 | 22.40 | 122,175.0 |
| TORRENT PHARMACEUTICALS LTD | 2,140.00 | 60.32 | 129,095.0 |
| DR REDDYS LABORATORIES LTD | 5,721.40 | 18.73 | 107,154.0 |
| MANKIND PHARMA LTD | 1,767.06 | 51.10 | 90,303.2 |
| ZYDUS LIFESCIENCES LTD | 4,973.40 | 18.58 | 92,392.4 |
| LUPIN LTD | 4,347.53 | 22.34 | 97,120.0 |
| AUROBINDO PHARMA LTD | 3,447.75 | 20.62 | 71,104.6 |
| ABBOTT INDIA LTD | 1,508.95 | 39.44 | 59,508.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs BAFNA PHARMACEUTICALS 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.58x |
| Max industry PE | 69.57x |
| Median industry PE | 39.44x |
| Average industry PE | 36.90x |
You may also like the below Video Courses